News | Radiation Dose Management | May 11, 2017

Large Nuclear Cardiology Laboratory Slashes Radiation Dose 60 Percent in Eight Years

Dose reductions achieved despite a large number of obese patients

Large Nuclear Cardiology Laboratory Slashes Radiation Dose 60 Percent in Eight Years

May 11, 2017 — A large nuclear cardiology laboratory in Missouri has slashed its average radiation dose by 60 percent in eight years, according to new research presented at ICNC 2017, May 7-9 in Vienna, Austria and published in JACC: Cardiovascular Imaging. The study in over 18,000 patients showed dose reductions were achieved despite a large number of obese patients.

“There has been concern amongst the medical community and the public that the radiation from medical diagnostic tests could increase the risk of cancer,” said Prof. Randall Thompson, a cardiologist at the Mid America Heart Institute, Kansas City, Missouri.

He continued: “Although the risk of harm from an individual nuclear cardiology test is very low — even very conservative estimates suggest only one in 1,000 extra patients would develop cancer 20 years later — the cumulative dose from multiple medical diagnostic tests may be a concern.”

Medical societies advocate getting radiation doses as low as is reasonably achievable. There are ways to do this but surveys show that adoption of new technologies, which cost money, and new testing algorithms, which take more physician time, has been slow.

This study assessed the impact on radiation dose of modifying protocols and introducing new hardware (cameras) and post-processing software in a large nuclear cardiology laboratory network in Kansas City.

The study included the 18,162 single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) studies performed at all four of the Saint Luke’s Mid America Heart Institute nuclear cardiology laboratories from Jan. 1, 2009-Sept. 30, 2016. SPECT MPI shows how well blood flows through the muscle of the heart and is primarily performed to diagnose the cause of chest pain or to help manage patients with known coronary artery disease..

Protocols were modified by performing stress-only tests where possible, which saves the radiotracer dose from the rest scan. Stress and rest scans are still required in some patients since shadowing from body parts can look like a lack of blood flow and two scans can clarify the findings. Technetium tracers are now used instead of thallium 100 percent of the time at one-third of the radiation dose.

Small field of view cameras which have advanced post-processing, and a new generation of camera systems which are more sensitive and need less radiotracer injected into the body, have both been introduced. These camera systems are equipped with advanced processing that enhances the nuclear pictures and need less radiation or shorter image acquisition times. Thompson’s laboratory focussed primarily on reducing the radiation dose.

The average radiation dose fell from 17.9 mSv in 2009 to 7.2 mSv in 2016 and the median dose (the 50th percentile) dropped from 10.2 mSv to 2.5 mSv. Thompson said: “There was a dramatic lowering of the radiation dose with all of these concerted efforts. The average dose fell by 60 percent and the median dropped by 75 percent.”

“The average dose had fallen to 5.4 mSv in 2012 but crept up as we’ve had more obese patients referred in whom we have to use the higher dose protocols,” he added. “But more than half of patients now are tested with a low-dose, stress-only test using the new technology, which is why the median dose of radiation has fallen so dramatically.”

The average background dose for people living in Europe and North America from radon underground and cosmic background sources is about 3 mSv a year. Medical societies consider higher and lower dose tests to be above 10 mSv and below 3 mSv, respectively. In 2010 the American Society of Nuclear Cardiology set a target of 9 mSv or less for the majority of tests.

Thompson said: “The majority of studies were in the high dose range back in 2009 and now most tests have a radiation dose that is about a third of the target. This is despite being referred a larger number of obese patients. In the last 2.5 years, 17 percent of patients have needed the large field of view camera as their average body mass index was 46 kg/m2 and they were simply too big for the small cameras.”

He concluded: “By adopting contemporary protocols and technologies it is feasible to substantially lower radiation doses in nuclear cardiology in very large numbers of patients in real world clinical practice.”

For more information: www.imaging.onlinejacc.org

 

Read the article "Recent Advances in Cardiac Nuclear Imaging Technology." 

Watch the VIDEO "PET vs. SPECT in Nuclear Cardiology and Recent Advances in Technology." An interview with Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and president-elect of the American Society of Nuclear Cardiology (ASNC), explained advances in PET and SPECT imaging. 

Watch the VIDEO "Trends in Nuclear Cardiology Imaging." A discussion with David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American Society of Nuclear Cardiology (ASNC), discusses advancements in nuclear imaging and some of the issues facing the subspecialty. 


Related Content

News | Cardiovascular Clinical Studies

March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led ...

Home March 13, 2024
Home
News | Cardiovascular Clinical Studies

March 13, 2024 — Silence Therapeutics has announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 ...

Home March 13, 2024
Home
News | Cardiovascular Clinical Studies

March 6, 2024 — Bodyport Inc., a biomarker-guided predictive care company focused on heart failure, announced data from ...

Home March 06, 2024
Home
News | Cardiovascular Clinical Studies

February 26, 2024 — More than 6 million Americans live with heart failure, and about half have an enlarged left ...

Home February 26, 2024
Home
News | Cardiovascular Clinical Studies

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart ...

Home February 21, 2024
Home
News | Cardiovascular Clinical Studies

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
News | Cardiovascular Clinical Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

Home January 03, 2024
Home
News | Cardiovascular Clinical Studies

December 19, 2023 — Peerbridge Health has announce the successful completion and findings of its prospective ...

Home December 19, 2023
Home
Subscribe Now